Skip to main content

Current Drug Targets aims to cover the latest and most outstanding developments on the medicinal chemistry and pharmacology of molecular drug targets e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal will be devoted to a single timely topic, with series of in-depth reviews, written by leaders in the field, covering a range of current topics on drug targets. These issues will be organized and led by a guest editor who is a recognized expert in the overall topic. As the discovery, identification, characterisation and validation of novel human drug targets for drug discovery continues to grow; this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.

Publisher: Bentham Science Publishers

Volume 12, Number 10, September 2011

Articles

Ulcerative Colitis: Pathogenesis
pp. 1373-1382(10)
Authors: Fries, Walter; Comunale, Salvatore

Favourites:
ADD

Genetics and Ulcerative Colitis: What are the Clinical Implications?
pp. 1383-1389(7)
Authors: Latiano, Anna; Annese, Vito

Favourites:
ADD

Natural History of Ulcerative Colitis: Current Knowledge
pp. 1390-1395(6)
Authors: Sandor Kiss, Lajos; Laszlo Lakatos, Peter

Favourites:
ADD

Is 5-ASA Still the Treatment of Choice for Ulcerative Colitis?
pp. 1396-1405(10)
Authors: Cottone, Mario; Renna, Sara; Modesto, Irene; Orlando, Ambrogio

Favourites:
ADD

Thiopurine Immunomodulators in Ulcerative Colitis: Moving Forward with Current Evidence
pp. 1406-1412(7)
Authors: J. La Nauze, Richard; P. Sparrow, Miles

Favourites:
ADD

Methotrexate: A Drug of the Future in Ulcerative Colitis?
pp. 1413-1416(4)
Author: Carbonnel, Franck

Favourites:
ADD

Mucosal Healing in Ulcerative Colitis: Where do we Stand?
pp. 1417-1423(7)
Authors: Fiorino, Gionata; Cesarini, Monica; Indriolo, Amedeo; Malesci, Alberto

Favourites:
ADD

How to Manage the Risk of Colorectal Cancer in Ulcerative Colitis
pp. 1424-1432(9)
Authors: Affendi Raja Ali, Raja; John Egan, Laurence

Favourites:
ADD

Biological Therapy for Ulcerative Colitis: What is after Anti-TNF
pp. 1433-1439(7)
Authors: Fiorino, Gionata; Cesarini, Monica; Danese, Silvio

Favourites:
ADD

Does Anti-TNF Therapy Reduce the Requirement for Surgery in Ulcerative Colitis? A Systematic Review
pp. 1440-1447(8)
Authors: Filippi, Jerome; B. Allen, Patrick; Hebuterne, Xavier; Peyrin-Biroulet, Laurent

Favourites:
ADD

Acute Severe Colitis: Infliximab and/or Cyclosporine?
pp. 1448-1453(6)
Authors: Fabro, Mauro; Szabo, Hajnalka; Terrosu, Giovanni; Avellini, Claudio; Tabuso, Maria; Fiorino, Gionata; Sorrentino, Dario

Favourites:
ADD

How to Manage Pouchitis in Ulcerative Colitis?
pp. 1454-1461(8)
Authors: Magro, F.; Lopes, S.; Rodrigues, S.; Azevedo, I.

Favourites:
ADD

Surgical Approach to Ulcerative Colitis: When is the Best Timing after Medical Treatment?
pp. 1462-1466(5)
Authors: Spinelli, Antonino; M. Sampietro, Gianluca; Bazzi, Piero; Sacchi, Matteo; Montorsi, Marco

Favourites:
ADD

Lessons to Learn from Crohn's Disease Clinical Trials: Implications for Ulcerative Colitis
pp. 1467-1477(11)
Authors: Jauregui-Amezaga, Aranzazu; Ricart, Elena; Panes, Julian

Favourites:
ADD

Evaluation of Dendrimer Safety and Efficacy through Cell Line Studies
pp. 1478-1497(20)
Authors: Kesharwani, Prashant; Gajbhiye, Virendra; K. Tekade, Rakesh; K. Jain, Narendra

Favourites:
ADD

Thiazolidinediones and Type 2 Diabetes: From Cellular Targets to Cardiovascular Benefit
pp. 1498-1512(15)
Authors: S. Papaetis, Georgios; Orphanidou, Dora; N. Panagiotou, Themistoklis

Favourites:
ADD

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more